P2RY12 and acute coronary syndrome: Guidelines recommend long-term OAC treatment for the secondary prevention of stroke in patients with AF (Kernan et al., 2014; Klijn et al., 2019) and OAC in combination with antiplatelet treatment—mainly P2Y12 inhibitors—in the case of acute coronary syndrome co-existence (Klijn et al., 2019; Hindricks et al., 2021).